Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    20879881 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Phase I Study of Investigational Medicinal Products in Children With Relapsed/Refractory Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Nivolumab;   Drug: Ch14.18/CHO
2 Recruiting NB2013-HR German (GPOH) / Dutch (DCOG) Trial
Condition: Neuroblastoma
Interventions: Drug: antibody ch14.18;   Drug: GM-CSF;   Drug: IL-2 i.v.;   Drug: IL-2 s.c.;   Drug: Retinoic acid
3 Recruiting A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Conditions: Sarcoma;   Osteosarcoma;   Neuroblastoma;   Melanoma
Interventions: Biological: Anti-GD2-CAR engineered T cells;   Drug: AP1903;   Drug: Cyclophosphamide
4 Completed NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors
Conditions: Solid Tumors;   Brain Tumors;   Sarcoma;   Pediatric Cancers;   Neuroblastoma
Interventions: Biological: Recombinant human interleukin-15 (rhIL-15);   Biological: NK Cell Infusion
5 Active, not recruiting Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Conditions: Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Recurrent Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Biological: Aldesleukin;   Biological: Dinutuximab;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Biological: Sargramostim

Indicates status has not been verified in more than two years